Nebumet is being developed to help prevent and treat lung metastases in dogs, while OmiCare AI is designed to support treatment monitoring through minimally invasive blood testing. The collaboration brings together therapeutic innovation and data-driven disease monitoring with the ambition of improving clinical decision-making, treatment follow-up, and quality of life for dogs with cancer.

The collaboration is intended to support further development and validation of both technologies in a European clinical setting, while also strengthening the foundation for future regulatory and commercial progress.

Jørund Sollid, CEO of Immuvera Therapeutics
“Our collaboration with OMICA strengthens the clinical and strategic potential of Nebumet. By combining treatment innovation with better monitoring tools, we are taking an important step toward a more integrated approach to veterinary oncology.”

Agustín Arasanz, CEO of OMICA Biomed
“This partnership demonstrates the real power of combining innovative therapeutics with advanced liquid biopsy and AI technologies. By aligning OmiCare AI with Nebumet, we are building a precision oncology ecosystem that can meaningfully improve outcomes and quality of life for dogs with cancer.”

The collaboration reflects a shared ambition to advance more precise and integrated cancer care in veterinary medicine. By combining complementary capabilities in therapeutics, diagnostics, and clinical development, Immuvera and OMICA aim to expand the tools available to veterinarians and improve outcomes for dogs at risk of metastatic disease.